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This article discusses the rationale of sedation in respiratory failure, sedation goals, how 
to assess the need for sedation as well as effectiveness of interventions in critically ill chil-
dren, with validated observational sedation scales. The drugs and non-pharmacological 
approaches used for optimal sedation in ventilated children are reviewed, and specifically 
the rationale for drug selection, including short- and long-term efficacy and safety aspects 
of the selected drugs. The specific pharmacokinetic and pharmacodynamic aspects 
of sedative drugs in the critically ill child and consequences for dosing are presented. 
Furthermore, we discuss different sedation strategies and their adverse events, such as 
iatrogenic withdrawal syndrome and delirium. These principles can guide clinicians in the 
choice of sedative drugs in pediatric respiratory failure.
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iNTRODUCTiON
Critically ill children who are mechanically ventilated often require sedative and/or analgesic drugs 
to diminish anxiety or pain and ensure comfort. Moreover, adequate sedation facilitates synchro-
nization with mechanical ventilation and enables invasive procedures to be performed. Adequate 
sedation has been described as the level of sedation at which patients are asleep but easily arousable 
(1). In pediatric intensive care unit (PICU) practice, this means that a child is conscious, breathes 
in synergy with the ventilator, and is tolerant of or compliant with other therapeutic procedures. 
However, the optimal level of sedation varies for each patient, depending on the type and severity of 
underlying disease and the need for certain therapeutic, invasive procedures.
To achieve the optimal level of sedation in individual patients, doses of sedatives are preferably 
titrated to effect based on observational sedation scales validated for the population in question. 
Nonetheless, it can be difficult to reach optimal sedation because of variability in plasma drug levels 
and response as well as in the patient’s clinical state. Both under- and oversedation are undesirable, 
as these conditions may adversely affect patient outcomes. Oversedation delays recovery, as greater 
sedatives consumption is associated with longer duration of ventilation as well as extubation failure 
(2). Part of this effect may be due to muscle weakness consequent to immobility (3). Oversedation 
also induces tolerance and withdrawal syndrome (4, 5). Undersedation, on the other hand, may cause 
distress and adverse events such as unintentional extubation or displacement of catheters, may lead 
to adverse memories (posttraumatic-stress syndrome) and increased need for nursing requirements. 
All this may lead to a longer PICU stay.
This article addresses how to assess the need for sedation, including relevant sedation scales, phar-
macokinetic (PK) and pharmacodynamic (PD) considerations of analgosedative drugs, sedation 
strategies, and long-term adverse effects of sedation, to guide clinicians to optimal sedation practice 
TABLe 1 | Characteristics of the COMFORT (behavior) scale and the State Behavior Scale.
instrument Parameter 
measured
Population 
(age)
exclusion criteria Observation items Score 
range
validation Cutoff 
points
item/
total
Reliability validity
COMFORT 
scale  
(9, 10)
Distress 37 
(newborn to 
17 years)
Seriously compromised neurological 
status, Profound mental retardation, 
Recent multiple trauma, Altered 
muscle ton or contractures, severe 
acute pain
Heart rate, mean arterial 
pressure, alertness, calmness, 
respiratory response, 
movement, muscle tone, facial 
expression
Numerical 
item: 1–5/
total: 
8–40
r = 0.84; 
p < 0.01 
(n = 50 paired 
obs) 
COMFORT 
vs. VAS 
r = 0.75; 
p < 0.01
OS ≤16
AS 17–29
US ≥30
COMFORT 
behavior 
scale (12)
Distress/
sedation
78 
(0–16 years)
Children with severe mental 
retardation, children with severe 
hypotonia, and patients receiving 
neuromuscular blockade
Alertness Numerical 
item: 1–5/
total: 
6–30
Kappa = 0.77–
1.0 (n = 40 
paired obs)
COMFORT 
behavior 
vs. NISS 
(Kruskal–
Wallis, 
p < 0.001)
OS ≤10
Calmness/agitation
Respiratory response or crying AS 11–22
Physical movement ICC = 0.99
Muscle tone US ≥23
Facial tension
State 
Behavior 
Scale (13)
Sedation/
agitation 
level
91 (6 weeks 
to 6 years)
Patients receiving neuromuscular 
blockade, postoperative patients, 
patients assessed to be in pain, 
unstable patients, patients at risk for 
opioid withdrawal
Respiratory drive, coughing, 
best response to stimuli, 
attentiveness to care provider, 
tolerance to care, consolability, 
movement after consoled
Bipolar 
numeric 
Item: −3 
to +1/
Total: −21 
to 7
Kappa = 0.44–
0.76 (n = 198 
paired obs) 
ICC = 0.79
SBS vs. 
NRS 
(F = 75.8, 
p < 0.001) 
Not done
PICU, pediatric intensive care unit; VAS, visual analog scale; NISS, nurse interpretation sedation score; SBS, state behavior scale; NRS, numeric rating scale; kappa, linearly 
weighted Cohen’s kappa; r, Pearson product correlation coefficient; obs, observations; OS, Oversedation; AS, Adequate sedation; US, undersedation; ICC, intraclass correlation 
coefficient.
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in pediatric respiratory failure. Moreover, we aim to elucidate 
the information gaps in current knowledge and propose future 
research directions.
SeDATiON ASSeSSMeNT
In order to provide adequate sedation, the level of sedation in criti-
cally ill children should be regularly assessed and documented. 
Furthermore, sedation assessment is needed to both determine 
the efficacy of sedatives and related interventions and to facilitate 
inter-institutional comparisons. Thus, the use of formal sedation 
assessment is recommended using a validated sedation scoring 
scale. Several behavioral assessment tools are described. The 
Ramsay and the Richmond Agitation Sedation Scale (RASS) are 
frequently used in critically ill children, but are only validated 
for adult ICU patients (6–8). The COMFORT scale (9, 10), the 
COMFORT behavior scale (11, 12), and the State Behavioral 
Scale (SBS) (13) are validated scores for PICU patients. The 
characteristics and psychometric properties of these scales are 
presented in Table 1.
The COMFORT scale was originally described in and validated 
for measuring discomfort in ventilated pediatric patients. This 
observational scale consists of two physiological items – heart 
rate and arterial blood pressure – and six behavioral items – 
alertness, calmness/agitation, respiratory response, physical 
movement, muscle tension, and facial tension. Because the 
physiologic variables are affected by inotropic and other drugs 
often used in pediatric intensive care, it was questioned whether 
their use contributes to the overall assessment of sedation in the 
individual patient. Therefore, the COMFORT scale was adapted 
in the COMFORT behavior scale, which does not include the two 
physiological items. Many psychometric properties of this scale 
have been tested (14–16). As well-sedated children do not always 
show unambiguous behavior, it was more realistic to define score 
ranges rather than cutoff points. Score range 6–10 was defined as 
oversedation; score range 23–30 as undersedation. Score range 
11–22 was defined as a gray area in which a second assessment, 
for example the Nurse Interpretation of Sedation Score (NISS), is 
recommended for clinical purposes (12, 17).
The SBS appraises seven behavioral dimensions; “Respiratory 
drive/response to ventilation,” “Coughing,” “Best response to 
stimulation,” “Attentiveness to care provider,” “Tolerance to care,” 
“Consolability,” and “Movement after consoled.” The score range 
from −3 to +3 and a score of 0 describes a patient who is alert and 
calm. Psychometric properties of this scale are good.
GeNeRAL CONSiDeRATiONS OF 
PHARMACOKiNeTiCS AND 
PHARMACODYNAMiCS iN CRiTiCALLY 
iLL CHiLDReN
The pharmacokinetic (PK) properties of a drug include the 
processes of absorption, distribution, metabolism, and excretion, 
while the pharmacodynamic (PD) properties comprise the actual 
responses to the administered drug and therefore may represent 
both efficacy and safety. In addition to the age-related variation 
in PK, critical illness and its treatment modalities impact PK and 
PD. These factors are summarized in Figure 1. Intrinsic factors 
related to the patient’s clinical condition include shifts in body 
fluid (altering volume of distribution), inflammation (altering 
drug transport and metabolism, clearance), and liver, renal, and 
FiGURe 1 | illustration of the effect of critical illness on pharmacokinetics of analgosedative drugs. With intravenous administration (upper left), drugs are 
injected directly into the central compartment: bioavailability is complete. With oral administration (lower left), gut absorption and first by-pass metabolism limit 
bioavailability. Analgosedative drugs are metabolized by the liver into more water-soluble metabolites that are excreted by the kidneys. Some analgosedatives have 
active metabolites (e.g., morphine and midazolam) that may accumulate with decreased renal function. A graphical representation of drug concentration over time 
depicts pharmacokinetics changes induced by critical illness: the dashed line represents the curve of a healthy individual while the solid line shows the change 
induced by critical illness. *Liver flow affects clearance of drugs with a high hepatic extraction ratio (e.g., propofol).
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heart failure (altering absorption, distribution, drug metabolism 
and excretion). Extrinsic factors include treatment modalities 
such as extra-corporeal membrane oxygenation (ECMO), hypo-
thermia, and continuous renal replacement therapy (18). Volume 
of distribution is often increased and clearance is altered either 
way in ECMO patients (19). Hypothermia leads to changes in 
volume of distribution due to redistribution of blood flow and 
a decreased clearance due to a decreased drug metabolizing 
enzyme activity (20, 21).
Furthermore, critical illness itself may be of influence on the 
effect of sedation. For instance, a critically ill child who is less 
reactive due to its underlying illness (e.g., sepsis) will respond 
differently to a sedative drug than a relatively healthy child 
who receives sedation for the acceptance of a tube after airway 
reconstruction.
Although the impact of separate aspects of critical illness on 
drug disposition is increasingly recognized, only few factors 
are actually taken into account in current dosing such as dos-
ing adjustments with renal failure. For sedative drugs, this 
underscores the importance of dosing and titrating the drugs 
to effect.
COMMONLY USeD AGeNTS
An ideal sedative drug exhibits anxiolysis, amnesia, and analgesia 
qualities, should be easily titrated to effect, and without any adverse 
effects. However, none of the existing drugs does meet all these 
qualities. Therefore, medications are commonly co-administered 
to compensate for any shortcomings and to achieve an optimal 
effect.
In PICU, benzodiazepines and opioids are frequently used 
agents. Despite the widespread use of sedatives in PICU, high-
quality data supporting appropriate dosing and safety are lacking 
(22). Many commonly used sedatives and analgesics in the PICU 
4Vet et al. Sedation in Critically Ill Children
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(e.g., lorazepam, dexmedetomidine, and fentanyl) are still used 
off-label, which means that their efficacy and safety have not been 
adequately proven (23). A rational choice for a particular agent 
is based on the desired effect of the drug, the interaction of the 
patient’s disease, and the side-effects of the drug (Table 2). These 
systemic effects can be adverse effects [e.g., propofol is avoided in 
patients with unstable hemodynamics due to its cardiodepressive 
properties (24)] or desired effects [ketamine is a bronchodilator 
used in asthma (25)]. Ideally, the choice for a particular agent 
should include its long-term effect on neurodevelopment. Most 
commonly used sedative and analgesics are neurotoxic in ani-
mals (26–28), which has caused uncertainty for their long-term 
safety in humans. Reassuringly, these animal data have not been 
confirmed in human studies. No adverse long-term effects of 
morphine administration at neonatal age were reported (29, 30). 
Moreover, short duration sevoflurane anesthesia in infancy does 
not appear to increase the risk of adverse neurodevelopmental 
outcome at 2 years of age compared with awake-regional anes-
thesia (31).
Benzodiazepines
Benzodiazepines (midazolam, and to a lesser extent lorazepam) 
are the most commonly used sedatives and the sedative of choice 
in many pediatric intensive cares (32). Midazolam is a central 
nervous system depressant that exerts its clinical effect by bind-
ing to a receptor complex, which facilitates the action of the 
inhibitory neurotransmitter gamma-amino butyric acid (GABA) 
in the brain. Through this effect, midazolam possesses sedative, 
anxiolytic, anticonvulsant, muscle relaxant, and amnesic prop-
erties (33). The amnesic effects of midazolam probably play an 
important role in the low levels of unpleasant experiences recalled 
by survivors of PICU treated with this agent (34).
Midazolam is metabolized to a major hydroxylated active 
metabolite (1-OH midazolam) by CYP3A4/5, and subsequently 
metabolized to 1-OH-midazolam–glucuronide by UGTs and 
renally excreted (35). A reduction of CYP3A activity as a result 
of inflammation, organ failure (36), or concomitant administra-
tion of other therapeutic drugs (drug–drug interactions) (37) 
may account for the failure of critically ill children to metabolize 
midazolam. In patients with renal failure, prolonged sedative 
effects may be caused by the accumulation of the active metabo-
lite, 1-OH midazolam–glucuronide (38).
Although most commonly used, midazolam is certainly not an 
ideal sedative agent. Adverse events associated with its use are not 
only tolerance, dependence, and withdrawal but also paradoxical 
hyperactivity (4, 5). In adults, continuous benzodiazepine use is 
associated with prolonged mechanical ventilation and length of 
ICU stay (39). Also, hypotension may occur and is most likely 
with bolus administration, particularly in neonates, in the setting 
of hypovolemia or concomitant use of morphine (40).
Lorazepam is a long-acting benzodiazepine used orally and 
intravenously. The use of intravenous lorazepam is limited by the 
fact that it is dissolved in propylene glycol, which can accumulate 
to produce metabolic acidosis and renal dysfunction (41, 42). 
For weaning, oral lorazepam is a good alternative for midazolam, 
because of its long half-live.
Opioids
Although opioids are analgesic drugs, they have sedative effects. 
Some PICUs use morphine as a first-line sedative while oth-
ers favor sedatives (mainly benzodiazepine) in the absence of 
suspected pain (43). Morphine provides sedation as well as 
analgesia and can be used as a single agent for analgesia and 
sedation.
As morphine clearance is substantially reduced in neonates 
less than 10 days of age, 1/3–1/2 of dosing in older children is 
needed to reach the same plasma levels as in older children. For 
analgesia, this dose reduction is related to adequate analgesia, 
but sedation data are lacking (44). Morphine has a relatively 
long duration of action of around 2 h when administered as a 
single dose intravenously (peak analgesic effect after 20  min). 
Morphine is characterized by hepatic metabolism (glucuro-
nidation) and renal excretion with intermediate volume of 
distribution. Therefore, its effects can be prolonged in patients 
with renal impairment. The impact of liver failure seems mild 
or moderate at best (45). Morphine stimulates the release of 
histamine and inhibits compensatory sympathetic responses, 
leading to vasodilation and consequently hypotension, particu-
larly following bolus administration (46). The opioid fentanyl 
has powerful analgesic properties and provides some sedation, 
as demonstrated in a randomized controlled trial comparing 
continuous fentanyl and remifentanil in postoperative orthope-
dic children (47). No studies are available for the use of fentanyl 
for long-term sedation in PICU. An important, but rare adverse 
effect is fentanyl-induced chest wall rigidity causing respiratory 
compromise, generally occurring after a large fentanyl bolus 
administration (48).
Alpha-Agonists
Clonidine and dexmedetomidine are central α-2 agonists with 
sedative and analgesic properties (49) increasingly used as 
first-line sedatives or as adjunct to other sedatives. Enthusiasm 
for these agents is driven by the absence of clinically significant 
respiratory depression (49, 50), which is an advantage in the 
spontaneously breathing patient or when extubation is planned 
(51). Moreover, they do not show neurotoxicity in animals (52), 
have opioid and benzodiazepine sparing properties (53, 54), and 
may decrease the incidence of withdrawal and delirium (55). A 
RCT comparing continuous intravenous clonidine and mida-
zolam in 129 ventilated children (30  days to 15  years) showed 
a similar sedative effect (56). Sedation under dexmedetomidine 
may more closely resemble natural sleep than sedation under 
benzodiazepines, although these theoretical advantages have not 
yet been demonstrated to improve patients’ perception of sleep 
in adult ICU (57, 58). For children, the use of dexmedetomidine 
is still off-label; it is approved for continuous sedative infusion in 
adults for 24 h.
The main adverse effect of alpha agonists is bradycardia/
arythmia and hypotension (49, 59), but these effects are rarely 
of clinical significance (54, 56). Data in children with severe 
hemodynamic compromise are insufficient to recommend their 
use in this particular population. To date, no study compared 
dexmedetomidine to clonidine in the PICU.
TABLe 2 | Drugs used for sedation in critically ill children and their PKPD considerations.
indications Dose elimination/metabolism effect of age on PK/PD Dosing adjustment in organ 
impairment
Livera Renal
Benzodiazepine
Midazolam Sedation/amnesia 50–300 mcg/kg/h i.v. Liver (CYP3A4/5) active metabolite: 
1-OH-midazolam and 1-OH-midazolam glucuronide
CYP3A4/5 activity is low at birth and 
reaches adult values in the first years of 
life (106)
Consider (107) Yes, in severe renal 
failure (108)
Lorazepam Sedation/amnesia 0.01–0.1 mg/kg/h i.v. Liver (glucuronidation by multiple UGT2B enzymes) UGT2B7 low at birth and increases with 
age (109)
Consider (110) No (108)
No active metabolite
α-2 agonist
Dexmedetomidine Sedation and 
analgesia
0.2–0.7 mcg/kg/h i.v. Liver (glucuronidation and mainly CYP2A6) Decreased clearance in children <1 years 
of age (111)
Yes No
No active metabolite
Clonidine Sedation and 
analgesia
0.5–2.5 mcg/kg/h i.v. 50% renal elimination/50% liver metabolism (mainly 
CYP2D6)
Decreased clearance in neonates Consider Yes/not significant
No active metabolite
Propofol Sedation and 
hypnotic
1–4 mg/kg/U i.v. <24 h duration Rapid and extensive liver metabolism (mainly 
CYP2B6)
Preterm neonates and neonates in the 
first week of life at increased risk for 
accumulation (112)
Consider (113, 
114)
No
No active metabolite
S-ketamine Analgesia and 
sedation
1–3 mg/kg/h (sedation) Liver metabolism (demethylation and hydroxylation) Appears similar to adults from 1 week 
onward (115)
Hepatotoxic 
(116) 
No
Active metabolite: norketamine (around three times 
less potent than ketamine)
Pentobarbital Sedation 1–5 mg/kg/h iv Liver (microsomal enzyme system) Reduced clearance in neonates (117) Consider (118) No (119)
No active metabolite
Opioids
Morphine Analgesia with 
sedation
5–40 mcg/kg/U i.v. Liver (glucuronidation by UGT2B7) Age-dependent increase in plasma 
clearance in children younger than 
10 years of age (109)
Consider (120) Initiate at lower 
dose and titrate 
slowly (121)
Active metabolite: morphine-6-glucuronide (more 
potent than morphine)
Fentanyl Analgesia and 
sedation
1–10 mcg/kg/h iv Liver (CYP3A4) NA Consider Yes
(Continued)
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eCMO Hemodynamic tolerance Relevant respiratory PD characteristics withdrawal
Benzodiazepine
Midazolam Increased Vd and 
drug loss in vitro 
(122, 123)
Hypotension with bolus dosing 
(124)
Respiratory depression ++ (5, 83)
Fall in cardiac output (125)
Lorazepam High drug loss 
in vitro (126)
Hypotension Respiratory depression ++ (83)
α-2 agonists
Dexmedetomidine No data Bradycardia and hypotension 
rarely of clinical significance
No significant respiratory depression, useful for 
extubation of in spontaneously breathing patient
Rebound hypertension and possible withdrawal after prolonged infusion (weaning 
required or switch to oral clonidine) (127)
Clonidine No data Bradyarrhytmia has been reported Rebound hypertension and withdrawal (weaning required)
Propofol High drug loss 
in vitro (19, 128)
Myocardial depressant Respiratory depression Irritability, jitteriness, and agitation on abrupt discontinuation after prolonged 
infusion (100)
No in vivo study Very quick emergence by stopping, useful during 
weaning of mechanical ventilation
Ketamine No data Usually preserved hemodynamic 
stability, but when endogenous 
stores of catecholamines have 
been depleted by stress or 
chronic illness ketamine can 
induce cardiovascular depression. 
No respiratory depression Delirium after prolonged use in adult
First-line sedative in asthma (Bronchodilator) No data in PICU
Barbiturate Increased Vd 
(129)
Hypotension, depression of 
cardiac contractility
Respiratory depression ++ (73)
Opioids
Morphine High drug loss 
in vitro (126, 130)
Histamine release leading to 
vasodilatation and hypotension, 
particularly following bolus dose 
Respiratory depression ++ (83)
Clearance and Vd 
changes during 
prolonged ECMO 
(131)
Use with caution in asthmatic patients due to 
potential histamine release
Fentanyl High drug loss 
in vitro (123, 130)
Large bolus doses can cause 
hypotension
Respiratory depression ++ (83)
aAll drugs that are significantly metabolized by the liver may need adjustment in fulminant acute liver failure, but not with mild increases of liver enzymes. Consider using only bolus doses and titrate to effect or use non-hepatically 
cleared drug like remifentanil.
TABLe 2 | Continued
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Propofol
Propofol has sedative and hypnotic properties. It involves GABA 
receptor activation (60) although its mechanism of action is 
not fully understood. Due to its strong cardio-depressant effect 
(24), its use should be avoided in the hemodynamically unstable 
patient. Long-term infusions in the PICU are contraindicated 
in the official drug label for children <16  years due the risk of 
lethal propofol infusion syndrome (PRIS). Any suspicion of PRIS 
(clinical and biological signs: metabolic acidosis, increased liver 
enzymes, lipemia, rhabdomyolysis, renal and cardiac failure) 
should lead to an immediate interruption of propofol infusion but 
despite discontinuation, death can ensue (61). Propofol infusion 
rate and duration, the presence of traumatic brain injury, and 
fever are factors associated with mortality in PRIS (62). The use 
of propofol should be limited; when used maximum infusion rate 
must not exceed 4 mg/kg/h with a maximum duration of 24 h (62).
Propofol’s very short half-live offers an advantage around the 
time of extubation (mainly in agitated patients): it allows weaning 
from the longer acting sedative inducing respiratory depression, 
control sedation during the time of extubation and ensure a quick 
recovery after. Therefore, in this special case, a short-term infu-
sion of propofol can be considered.
Ketamine
Ketamine is an NMDA receptor antagonist (63) with cataleptic, 
amnestic, and analgesic properties. It maintains hemodynam-
ics (64, 65) by inducing release of endogenous catecholamine 
(65). However, in patients with hemodynamic compromise and 
chronic illness or stress who have depleted catecholamine stores, 
it can decrease myocardial contractility and even induce collapse 
(66, 67). Ketamine is used in the PICU as a co-analgesic with 
opioids for pain control (low dose, around 0.1 mg/kg/h) (68) and 
occasionally when usual sedative agents fail to provide adequate 
sedation (high dose, 1–3 mg/kg/h). Due to its bronchodilatory 
properties, it is the first-line analgosedative in status asthmaticus 
(25, 69). A very common adverse effect of ketamine is the occur-
rence of hallucinations, and therefore low dose of benzodiazepines 
should be co-administered. Early work hints at its potential to 
elevate intracranial pressure (70) and many physicians still avoid 
its use in traumatic brain injury despite more recent work not 
showing this effect (71).
Antihistamines
Promethazine, alimemazine, and diphenhydramine are first 
generation antihistamines with anti-dopaminergic and anticho-
linergic drug actions. These drugs may produce significant seda-
tion as well as quiescence. A combination of oral chloral hydrate 
and promethazine was more effective than midazolam infusion 
for maintenance sedation in critically ill children, but less than 
half the patients in each study arm reached target sedation during 
study period (72). No other studies are available, and therefore, 
evidence to use antihistamines for (long-term) sedation in PICU 
is low.
Barbiturates
Pentobarbital and thiopental are primarily used for therapy-resist-
ant status epilepticus, but its use as sedative in therapy-resistant 
agitation has also been reported (73, 74). Barbiturates are highly 
lipid soluble. Given by infusion, it accumulates in adipose tissue 
whence it diffuses slowly back to the blood after infusion cessa-
tion. This, coupled with a long half-life (5–10 h), is responsible for 
the persistence of sedation after infusion cessation. Barbiturates 
are also associated with high rates of adverse events, including 
hypotension, depression of cardiac contractility, severe skin 
and mucous reactions (Stevens Johnson syndrome and Toxic 
Epidermal Necrolysis), and neurologic sequelae (73). Life-
threatening hypokalemia and rebound hyperkalemia have been 
observed after cessation of thiopentone coma for intracranial 
hypertension. As this has not been observed with other underly-
ing diseases or with pentobarbital, its cause is likely due to an 
association between the underlying clinical symptoms and 
thiopentone (75).
Neuro-Muscular Blockers
Analgesia and profound sedation have to be ensured before start-
ing neuromuscular blockade. Neuromuscular blocking agents are 
associated to critical illness polyneuropathy and myopathy and 
therefore should be restricted to special circumstances, discon-
tinued as soon as possible and used at the smallest possible dose 
(76, 77). The level of evidence supporting their prolonged use for 
particular indications is poor (76, 78). They are recommended 
if effective mechanical ventilation cannot be achieved despite 
profound sedation [e.g., ARDS (77), severe asthma (25, 79)]. 
They are often used in case of severe cardio-vascular instability, 
but their benefit may be limited because only modest decrease 
in energy consumption is achieved compared to profound seda-
tion (80, 81). Other common uses are refractory pulmonary and 
intracranial hypertension (82).
SeDATiON STRATeGieS
Optimizing sedation in the critically ill is of major importance. In 
general, the current tendency is to lighten sedation in the intensive 
care to avoid delayed recovery with longer duration of ventilation 
(2), tolerance, and withdrawal (5, 83). Despite the awareness of 
the adverse effects of oversedation, it remains common practice 
in the PICU (84). Sedation strategies play a key role to achieve 
adequate sedation (Box 1).
Protocolized Sedation
To optimize sedation in critically ill children, it is recommended to 
assess levels of sedation and to titrate sedatives and analgesics on 
the guidance of sedation protocols or algorithms. Implementing 
a sedation protocol allows targeting patient-specific sedation 
goals. In the adult intensive care, protocol implementation 
decreases days of mechanical ventilation and ICU stay (85). But 
more recently, adult studies failed to show these positive effects 
(86). These changes in results over time may be explained by the 
growing awareness of the deleterious effect of oversedation and 
general tendency to avoid it. In the PICU, the effect of protocol-
izing sedation is less clear, but studies are recent and avoidance 
of oversedation may already have entered the practice. Several 
non-randomized trials reported conflicting results on the impact 
of protocolized sedation on outcomes like length of PICU stay, 
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duration of mechanical ventilation, or the need for analgesia and 
sedation (87). Recently, in a large cluster randomized trial among 
children undergoing mechanical ventilation for acute respiratory 
failure, the use of a sedation protocol compared to usual sedation 
practice did not improve clinical outcome (88).
Daily Sedation interruption
Another approach to potentially avoid the negative effects of 
oversedation, and especially the adverse effects of continuous 
benzodiazepine use, is daily sedation interruption (DSI). In 
adults, clinical trials have shown that DSI can reduce the duration 
of mechanical ventilation, hospital stay, and amount of sedatives 
administered, without compromising patient comfort or safety 
(89). Several later studies have confirmed this beneficial effect 
(90), whereas other studies, in different settings, showed no 
benefit (91, 92).
In critically ill children, two pilot studies showed that DSI 
is feasible and safe, even in ECMO patients, but both studies 
were not designed to detect differences in clinical outcome (93, 
94). Another study, comparing DSI with continuous sedation 
in children, DSI led to improved clinical outcomes, including 
shorter durations of mechanical ventilation and PICU stay (95). 
In a recent study comparing DSI  +  protocolized sedation to 
protocolized sedation only, no beneficial effect of DSI was found 
(96). DSI did not reduce the duration of mechanical ventilation, 
length of stay, or the amounts of sedative drugs administered. 
There are important differences between these studies in study 
design (DSI and Standard of Care arm vs. DSI +  protocolized 
sedation and protocolized sedation arm), setting (India vs. 
Europe), patient population (e.g., high incidence of neurotrauma 
vs. respiratory infection), and ICU practices (e.g., longer mean 
duration of mechanical ventilation, more sedatives and neuro-
muscular blockers administered in the first study) (97). For the 
latter study (DSI + PS vs. PS), the effect of protocolized sedation 
itself on the clinical endpoints might have outweighed the effect 
of DSI, as also demonstrated in adults (91).
Drug Cycling
Some PICUs use drug “cycling” or “rotation” as a method of 
decreasing the adverse effects of continuous sedation (98). This 
strategy is aimed at preventing tachyphylaxis and tolerance by 
“cycling” drug combinations. For example, an opioid and benzo-
diazepine regimen can be changed to ketamine and promethazine, 
followed by clonidine and chloral hydrate, all on a weekly basis. 
However, to the best of our knowledge, evidence supporting the 
beneficial effects of “cycling” is lacking.
ADveRSe eFFeCTS
withdrawal
Prolonged administration of analgesics and sedatives in critically 
ill children may induce drug tolerance and physical dependency. 
Abrupt discontinuation or too rapid weaning of these drugs in 
physically dependent children may cause withdrawal syndrome. 
Symptoms of benzodiazepines and opiates withdrawal can 
broadly be distinguished into three groups: (1) overstimulation 
of the central nervous system (e.g., agitation, tremors, anxiety, 
and hallucinations), (2) autonomous dysregulation (e.g., sweat-
ing, fever, tachycardia, and tachypnea), and (3) gastro-intestinal 
symptoms, which have only been described in opiate withdrawal 
(99). Withdrawal syndrome has been particularly reported after 
administration of opioids and benzodiazepines. The onset of 
withdrawal syndrome depends on the half-life of the drug and 
can be after 1  h or up to several days after discontinuation of 
these drugs (100). Both longer duration of administration and 
high total doses of opioids and/or benzodiazepines are clearly 
related with the occurrence of withdrawal syndrome in critically 
ill children, and may therefore be considered risk factors (83, 99). 
Moreover, the exact biochemical mechanisms responsible for 
the development of withdrawal syndrome remain unclear. The 
reported prevalence of withdrawal syndrome in critically ill 
children who had received benzodiazepines and/or opioids for 5 
or more days ranges from 17 to 57% (99, 101).
The development of pediatric scoring tools for withdrawal 
syndrome is a huge step forward. Two validated assessment 
tools for observing and identifying withdrawal syndrome after 
long-term use of benzodiazepines and opioids in PICU patients 
have been described. These are the Withdrawal Assessment Tool 
version-1 (WAT-1) and the Sophia Observation Withdrawal 
Symptoms-scale (SOS) (102–105). Table  3 provides details on 
BOX 1 | Practical recommendations for physicians.
Step 1. Assessment
 – Use a validated sedation scale and train all nurses to adequately use this 
scale.
 – Assess the level of sedation in critically ill children regularly (e.g., 
COMFORT-b scale every 8 h and additionally in case of distress and after 
interventions).
 – Identify the desired level of sedation for the individual patient and act when 
over- or undersedated.
Step 2. Non-pharmacological treatment
 – Reduce distress by nursing and parenting interventions.
Step 3. Pharmacological treatment
 – Titrate the sedatives to achieve the optimal level of sedation for that 
individual patient.
 – Start with one drug, choice preferably protocolized: e.g., midazolam, 
lorazepam, morpine, or fentanyl and titrate up.
 – If distress, add one drug from other class, e.g., opioid when already 
benzodiazepine.
 – If sedation is still insufficient with these two drugs, add clonidine, dexme-
detomidine, or ketamine, consider switching benzodiazepine or opioid.
 – Always give a bolus dose with increase of infusion, to quickly reach steady-
state unless the patient is hemodynamically too unstable, than consider a 
bolus dose in 30 min.
 – If all sedatives fail, consider pentobarbital and discontinue other drugs. Be 
careful with abrupt discontinuation of α2-agonists (rebound hypertension) 
and opioids.
Step 4. Weaning and delirium
 – Decrease sedatives based on sedation scores.
 – Add withdrawal and delirium score at regular intervals.
 – If a patient received sedatives >5 days, consider slow tapering or switch 
to long-acting oral drugs.
 – When scores suggest delirium, consult psychiatrist for diagnosis.
 – When antipsychotics are considered necessary: start low, go slow, moni-
tor adverse events.
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TABLe 3 | Symptoms and psychometric properties of the wAT-1 and SOS.
instrument Population Observation items Structure Psychometric evaluation withdrawal 
cut-off scores
Total items Score-range Reliability validity
Withdrawal 
Assessment 
Tool version 
1 (WAT-1) 
(102, 103)
Children Tremor 11 Numerical 0–12 Internal: PRINCALS, 4 factors Construct: Sen. = 0.87, Spec. = 0.88 ≥3
Uncoordinated/repetitive 
movement
rs: 0.80 (between WAT-1 score and NRS-withdrawal)IRR
N = 30 paired observationsYawning or sneezing Peak WAT-1 scores for each subject correlated moderately 
with total cumulative opioid exposure (r = 0.23, p = 0.009), 
cumulative benzodiazepine preweaning (r = 0.30, p < 0.001) 
and total (r = 0.33, p < 0.001) exposure
State ICC = 0.98
Cohen’s kappa = 0.80Loose/watery stools
Vomiting/retching/gagging
Temperature >37.8°C Sensitivity to change
N = 51 episodes of withdrawal (in 21 pts) WAT-1 scoreSweating
 – before rescue therapy: 6 (4–8)
 – after after rescue therapy: 2 (1–3) (Wilcoxon–signed rank 
test p < 0.001)
State
Startle to touch
Time to gain calm state (SBS ≤ 0)
Sophia 
Observation 
withdrawal 
Symptoms-
scale (SOS) 
(104, 105)
Children Tachycardia, tachypnea, fever 
(≥38.5°), sweating, agitation, 
anxiety, tremors, increased 
muscle tone, inconsolable crying, 
grimacing, sleeplessness, motor 
disturbance, hallucinations, 
vomiting, and diarrhea
15 Numerical 0–15 Internal: MDS, 3 dimensions Construct ≥4
85 experts
IRR: N = 23 paired 
observations, ICC = 0.97
Construct
Sen. = 0.83
Spec. = 0.93
rs: 0.51 95% CI 0.32–0.66, p < 0.001) cumulative doses of 
benzodiazepines
Cohen’s kappa = 0.73–1.0 
(items)
rs: 0.39 (95% CI 0.17–0.57, p < 0.01) cumulative doses of 
opioids
Sensitivity to change
N = 156 paired SOS assessments in 51 pts
Decrease SOS score: 1.47 (95% CI, −1.91 to −1.04) after 
rescue therapy
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symptoms and psychometric properties of the WAT-1 and SOS. 
The WAT-1 is an 11-item scale and scores of three or higher (on 
a scale of 0–12) which indicates that the child is suspected for 
withdrawal. The SOS consists of 15 items and is based on the 
underlying empirical structure of co-occurrences of withdrawal 
symptoms that experts considered relevant. A SOS score of 4 or 
higher reflect a high probability of withdrawal.
Strategies to reduce the prevalence of withdrawal syndrome 
should begin by making active efforts to reduce doses of ben-
zodiazepines and/or opioids during the whole ICU course, and 
thereby preventing oversedation. As discussed above, DSI does 
not appear to add to protocolized sedation to reach this goal. 
Protocolized sedation targeting at conscious sedation appears at 
this time the best available approach.
A weaning strategy for gradual decreasing of opioid and/or 
benzodiazepine dosages once the patient is recovering may be 
effective to prevent withdrawal syndrome. Strategies include 
slowly tapering off the intravenous infusion rate over time, using 
an alternative route, e.g., enteral or subcutaneous, or transition 
to long acting drugs like methadone from morphine/fentanyl 
or lorazepam from midazolam. Disappointingly, little evidence 
is available on efficacy or safety of different weaning strategies. 
Weaning strategies ranging from 10 days to several months have 
been evaluated in observational (retrospective and prospective) 
studies (132–136). Two negative RCTs evaluated methadone 
weaning in 5 vs. 10 days (137) and a high- vs. low-dose metha-
done schedule in children (138). And while target drug levels for 
sedative and opioid dependence have been established for adults, 
they are lacking for children, as are PK data. Hence, we can not 
advise on the optimal weaning strategy or preferred drugs in 
pediatric ICU withdrawal.
Nevertheless, some suggestions to reduce withdrawal syn-
drome while avoiding unnecessary prolonged drug use can be 
made. First, awareness among clinicians on the risk factors for 
withdrawal symptoms may aid to prevent a too rapid reduction in 
drug doses. Moreover, it may lead to a faster switch from IV, short 
half life drugs to oral or subcutaneous, long half-life drugs. This 
may also facilitate faster ICU discharge. Second, regular monitor-
ing of withdrawal symptoms with validated scales will also help 
to faster diagnose and treat withdrawal as well monitoring of the 
effect of interventions.
Pediatric Delirium
Pediatric intensive care staff has become more alert to the occur-
rence of delirium in their patients – not least since studies showed 
an estimated incidence of 4–29% (139–141). The core diagnostic 
criteria for delirium are (a) disturbance of consciousness with 
reduced ability to focus, shift or maintain attention; (b) change 
in cognition (such as memory deficit, disorientation, language 
disturbance) or development of a perceptual disturbance; (c) 
the disturbance develops over a short period of time and tends 
to fluctuate during the course of the day. The pathogenesis of 
delirium is largely unknown. The sufferers may be hyperactive, 
hypoactive, or show signs of both states. Typical for the hypoac-
tive delirium are slowed or sparse speech, hypoactive or slowed 
motor activity as well as lethargy or also described as reduced 
awareness or apathy. A number of delirium symptoms overlap 
with those observed in other conditions, such as pain and with-
drawal syndrome (99).
Adults and children largely show the same symptoms although 
hallucinations, cognitive changes and hypoactive delirium are 
difficult to diagnose in the very young, preverbal PICU popula-
tion. For this reason, PD is underdiagnosed in this age group 
(139, 141). Another reason is that nurses and physicians may not 
specifically focus on the symptoms of PD. Still, it is also possible 
to assess PD in this vulnerable age group by carefully observing 
behavior (139, 142, 143). Diagnosing of PD in the PICU setting 
requires a reliable, validated, and clinically useful bedside tool 
that may also serve for screening and guiding of treatment. This 
is an area in full development but several suitable instruments 
are already available: the pediatric Confusion Assessment 
Method for ICU (pCAM-ICU) (141), the Cornwell Assessment 
Pediatric Delirium tool (CAP-D) (140, 144), and the Sophia 
Observation withdrawal Symptoms-Pediatric Delirium scale 
(SOS-PD) (145). Haloperidol and risperidone are antipsychot-
ics used for delirium in critically ill children and also adults. To 
date, studies showing benefit of antipsychotics to prevent or treat 
ICU delirium are lacking. Moreover, in a retrospective cohort 
of critically ill children, almost 10% of children showed severe 
adverse events associated with haloperidol treatment, including 
extrapyramidal syndrome (146). Hence, while ICU delirium has 
been associated with an increased risk of mortality, it is unclear 
if the benefits of antipsychotic treatment outweigh the risks. In 
the Netherlands, the Dutch Pediatric Drug Handbook (www.
kinderformularium.nl) advices a low haloperidol starting dose 
to be carefully titrated to effect, while diligently monitoring 
potential side effects.
NON-PHARMACOLOGiCAL APPROACH
Drug therapy is the most obvious treatment modality of 
distress, withdrawal syndrome and delirium in critically ill 
children. Increasingly, the importance of non-pharmacological 
interventions is recognized. Such interventions use a multi-
component approach, which including repeated reorientation, 
early mobilization, noise reduction (use of ear plugs), and a 
non-pharmacological sleep management. We suppose that these 
interventions could reduce distress and delirium, but evidence is 
limited. However, common sense suggests that these interven-
tions (for example, promoting orientation and day-night rhythm, 
and avoiding overstimulation by light and sounds) may be effec-
tive for children as well.
Another strategy is adaptation of the environment, like noise 
reduction. Noise is a major environmental factor to cause anxi-
ety and sleep disturbance in critically ill patients (32). In a way, 
noise reduction could well be effective in decreasing anxiety. It 
would be worthwhile, therefore, to reduce noise in the PICU as 
much as possible. All in all, based on the limited evidence it is 
difficult to extrapolate the effectiveness from adults to children. 
However, common sense has it that most of the interventions, 
for example promoting orientation and day–night rhythm and 
avoiding overstimulation by light and sounds, may be suitable for 
children as well, so as to create a comfortably calm environment 
for child and parents. Adult data show a reduction in delirium 
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rates with a multifaceted approach, not only including lighter 
sedation approaches, but also non-pharmacological changes as 
noise reduction and aids for patients to better orientate them-
selves (147).
FUTURe ReSeARCH
Despite the widespread use of sedatives to facilitate mechanical 
ventilation in pediatric intensive care, evidence to guide clinical 
practice is remarkably scarce. Only few adequately powered, well-
designed RCTs to study efficacy and safety of individual drugs 
or their combinations have been performed. Several roadblocks 
to the conduct of these trails have been identified and should 
be taken into account with the design of future studies. Hence, 
robust study design including adequate power calculation, rand-
omization procedures and blinding. (International) multi-center 
design is very likely needed to reach adequate sample size and 
high likelihood of generalizability. This adds complexity to the 
trial and asks a tremendous effort in training of local nurses, 
physicians and other study personnel. Validated sedation scales 
for the specific population, e.g., also taking into account age of 
patient and patient-controlled or nurse-controlled, must be used 
to assess sedation level in children.
Further, especially in critically ill children, “gate keeping,” 
i.e., not including the sickest patients for fear of overburdening 
patients and parents, presents an important challenge toward 
adequate recruitment. But, previous studies have shown that 
these challenges can be overcome and taking them into account, 
future research could focus on the following aspects of pediatric 
sedation in the ICU:
 – Does protocolized sedation indeed improve clinical outcome? 
Preferably, short-term outcomes like as ventilator-free days, 
extubation readiness, withdrawal syndrome and long-term 
outcomes, like neurodevelopmental outcome, occurrence of 
PTSD and quality of life should be evaluated. This should also 
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